US20020164286A1 - Methods for obtaining fluid and cellular material from a breast duct - Google Patents
Methods for obtaining fluid and cellular material from a breast duct Download PDFInfo
- Publication number
- US20020164286A1 US20020164286A1 US10/175,022 US17502202A US2002164286A1 US 20020164286 A1 US20020164286 A1 US 20020164286A1 US 17502202 A US17502202 A US 17502202A US 2002164286 A1 US2002164286 A1 US 2002164286A1
- Authority
- US
- United States
- Prior art keywords
- breast
- breast duct
- duct
- fluid
- washing fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000481 breast Anatomy 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 43
- 239000012530 fluid Substances 0.000 title claims abstract description 33
- 239000000463 material Substances 0.000 title claims description 12
- 230000001413 cellular effect Effects 0.000 title claims description 9
- 238000005406 washing Methods 0.000 claims abstract description 27
- 230000002380 cytological effect Effects 0.000 claims abstract description 9
- 210000002445 nipple Anatomy 0.000 claims description 37
- 238000002372 labelling Methods 0.000 claims description 34
- 239000003550 marker Substances 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims 3
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 206010006187 Breast cancer Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 230000027455 binding Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 210000000981 epithelium Anatomy 0.000 description 8
- 230000001530 keratinolytic effect Effects 0.000 description 8
- 102000011782 Keratins Human genes 0.000 description 7
- 108010076876 Keratins Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000007298 Mucin-1 Human genes 0.000 description 4
- 108010008707 Mucin-1 Proteins 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010006223 Breast discharge Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 2
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 2
- 108010066327 Keratin-18 Proteins 0.000 description 2
- 108010070511 Keratin-8 Proteins 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000012760 immunocytochemical staining Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000218194 Laurales Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000007387 excisional biopsy Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000003159 intraductal papilloma Diseases 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- -1 typically aqueous Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0041—Detection of breast cancer
Definitions
- the present invention relates generally to medical methods and devices for accessing body lumens and in particular to methods and apparatus for identifying ductal orifices in human breasts and accessing the ducts through the identified orifices.
- fluids from the breast ducts have been externally collected, analyzed, and correlated to some extent with the risk of breast cancer.
- Such fluid collection is generally taken from the surface of the nipple and represents the entire ductal structure.
- Information on the condition of an individual duct is generally not provided.
- Information on individual ducts can be obtained through cannulation and endoscopic examination, but such examinations have been primarily in women with nipple discharge or for research purposes and have generally not examined each individual duct in the breast.
- ductal access may be obtained by a magnification of the nipple and identification of ductal orifice(s) using conventional medical magnifiers, such as magnification loupes. While such magnified examination is relatively simple, it cannot be relied on to identify all orifices.
- ductal orifices can be confused with other tissue structures, such as sebaceous glands and simple keratin-filled caruncles of the nipple.
- tissue structures such as sebaceous glands and simple keratin-filled caruncles of the nipple.
- the present invention provides improved methods, kits, and other apparatus for locating breast ducts in the breasts of human female patients.
- the methods of the present invention permit reliable identification of the orifices within the nipple of a breast which lead to each of the multiple ductal networks within the breast. By reliably identifying each orifice, all of the ductal networks can be located and subsequently accessed for diagnostic, risk assessment, therapeutic, research, or other purposes.
- a method for locating an orifice of a breast duct comprises labelling ductal cells disposed at the ductal orifice with a visible or otherwise detectable label. The orifice may then be located based on the presence of the label at the orifice. Specific and preferred methods for labeling the orifices are described below in connection with a second aspect of the present invention.
- an access device such as a catheter or fiberoptic viewing scope, can be introduced through at least one of the orifices and into the associated breast duct.
- the method may further comprise introducing the same or a different access device through other orifices, often into each of the orifices to permit diagnosis, treatment, or other evaluation of all of the ductal networks of a breast.
- the present invention comprises a method for labelling the orifice of a breast duct.
- the method includes treating a nipple to expose tissue in an orifice of each duct.
- the treated nipple is then exposed to a labelling reagent capable of specifically binding to a tissue marker characteristic of tissue at the ductal orifice. Binding of the labelling reagent to the tissue results in immobilization of a label at the orifice, permitting subsequent location of the orifice as described above.
- the treating step preferably comprises washing the nipple with a keratinolytic agent, such as 5% to 50% acetic acid (by weight), to remove keratin-containing materials which normally occlude the duct orifice and which could inhibit binding of the labelling reagent to the tissue marker.
- a keratinolytic agent such as 5% to 50% acetic acid (by weight)
- the tissue marker is typically characteristic of the ductal epithelium and represents either a membrane antigen or a cytoplasmic antigen. It has been found by the inventors herein that the ductal epithelium extends to within 0.1 mm to 0.2 mm of the nipple orifice and is sufficiently exposed to the surface of the nipple to permit labelling according to the methods of the present invention.
- the labelling reagent comprises a polyclonal or monoclonal antibody or other specific binding substance specific for the marker.
- the antibody may be directly labelled with a visible label, such as a fluorescent label, a dye label, a chemiluminescent label, or the like.
- the labeling reagent may comprise two or more components, typically including a primary antibody which is specific for the marker and one or more secondary binding substances which bind to the primary antibody and provide a label, optionally a magnified label.
- the primary antibody may be unlabelled, and a secondary labelled antibody specific for the primary antibody also be provided.
- the primary antibody can be labelled with biotin or other hapten, and binding of the label provided via avidin, secondary antibody specific for the hapten, or the like. Numerous specific techniques for labelling of antigenic tissue markers are well known and reported in the immunocytochemical staining literature.
- a method according to the present invention comprises labelling cellular material at a ductal orifice with a visible label and subsequently accessing the duct through the labelled orifice.
- the labelling step usually comprises the method set forth above.
- the accessing step may comprise introducing an access device through at least one of the labelled orifices, and preferably through all of the labelled orifices, where the access device may be a catheter, a fiber optic viewing scope, or the like.
- kits for labelling breast duct orifices comprises a labelling reagent or reagents capable of specifically labelling a cellular marker at the ductal orifice, instructions setting forth a labelling method as described above, and a package containing the labelling reagent and the instructions for use.
- the kits of the present invention will further include the keratinolytic agent and any other reagents that may be necessary for performing the method.
- Instructions for use will set forth the use of all provided reagents and may further set forth the use of agents which are available in the laboratory where the assay is to be performed.
- a kit for accessing a breast duct comprises a labelling reagent capable of specifically labelling a ductal orifice and optionally a keratinolytic agent for treating the nipple prior to exposure of the labelling reagent.
- the kit further comprises an access device capable of being inserted through a labelled ductal orifice to a ductal lumen, such as a catheter, a fiber optic viewing scope, or the like.
- the kit still further comprises a package containing the labelling reagent, optionally the keratinolytic agent, and the access device.
- the accessing kit may further comprise instructions for use setting forth a method comprising the accessing steps as described above.
- FIG. 1 is an anterior view of a human female breast, shown in section, and illustrating three of the six to nine ductal networks extending inwardly from the nipple.
- FIG. 2 is an enlarged view of the nipple of FIG. 1 illustrating the orifices leading to each of the three ductal networks.
- FIG. 3 is a still further enlarged view of a single orifice illustrating the distribution of tissue markers from the epithelium to the opening of the orifice, where such markers at the opening are available for binding to labelled antibodies.
- FIG. 4 is a schematic illustration of the appearance of a nipple which has been labelled with visible markers according to the methods of the present invention.
- the present invention comprises methods for locating, labelling, and accessing the ductal networks in human female breasts.
- a typical breast B is illustrated in FIG. 1 and includes a nipple N and from six to nine ducts D.
- each ductal network D 1-3 begins with an orifice O 1-3 which lies at the surface of the nipple N and extends inwardly through a ductal sinus S 1-3 and then into a branching network.
- Each network D comprises a series of successively smaller lumens which are arranged in complex, three-dimensional patterns.
- the networks of each duct will overlap within the breast tissue but will not be interconnected.
- the present invention relies on identifying and labelling tissue in the orifice O of each duct D within the nipple N.
- ductal networks there will be from six to nine orifices which open into a like number of ductal networks.
- An abrupt transition from the ductal epithelium to the squamous epithelium of the skin is found within about 0.1 mm to 0.2 mm of the nipple surface.
- the ductal orifice will be occluded with a conical keratin plug measuring about 0.5 mm to 1 mm in size.
- the present invention relies on the specific labelling of tissue markers at the orifice of selected one(s) or all of the ductal network(s).
- specific it is meant that the label will be introduced in a manner such that it will bind to the orifice region within the nipple but not bind (or will bind to a significantly lesser extent, usually at least 10-fold less) to other regions of the nipple. In this way, binding of the label to the orifice will be a discernable indication that the orifice is present and available for access to the associated ductal network.
- the tissue marker(s) will be an antigenic or epitopic site characteristic of the epithelial lining of the breast duct. Surprisingly, it has been found that the epithelial lining extends sufficiently far into the orifice region of the duct to permit successful labelling using generally conventional immunocytochemical labelling reagents and techniques, as described in more detail below.
- tissue markers include antigens and epitopes defined by the cytokeratins present in the epithelial cytoplasmic lining, such as cytokeratin 8, cytokeratin 18, and by molecules present in the membrane lining, such as E cadherin, epithelial membrane antigen (EMA), and the like.
- Suitable breast epithelial tissue markers are described, for example, in Moll et al. (1982) Cell 30:11-19; Gown and Vogel (1984) Am. J. Pathol. 114:309-321; and Johnson (1991) Cancer Metastasis Rev. 10:11-22.
- an orifice region O of a ductal network D is illustrated with a plurality of markers M lining the epithelium of the duct and extending to the perimeter of the orifice.
- Labelled antibodies A can be used to locate and label those markers M which are near the orifice O. Frequently, it will be desirable or necessary to wash the nipple with a solution capable of unblocking the orifice to permit binding of the antibodies or other labelling reagent.
- the orifice can frequently become plugged with keratin-containing materials, and washing with a keratinolytic solution, such as acetic acid (5% to 50% by weight) admixed in a pharmaceutical delivery vehicle, will expose sufficient marker sites at each orifice to enable labelling according to the methods of the present invention.
- a keratinolytic solution such as acetic acid (5% to 50% by weight) admixed in a pharmaceutical delivery vehicle
- the labelled antibodies or other labelling reagents may be formulated as liquid, typically aqueous, solutions in a generally conventional manner.
- Suitable anti-cytokeratin antibodies may be obtained from commercial suppliers, with specific antibodies including FITC-anticytokeratin (Becton-Dickenson), CAM 5.2, and the like.
- the antibodies may be coupled to one member of a signal-producing system capable of generating a detectable visual or other change on the tissue surface, where an element will be referred to here and after as a “visual label.”
- Suitable signal-producing systems include fluorescent systems, color-generating systems, and luminescent systems.
- the primary antibody can be mouse IgG and the labelled secondary antibody can be FITC goat anti-mouse IgG (Zymed).
- Such signal-producing systems and the use on tissue and tissue samples is well described in the medical, scientific, and patent literature relating to immunocytochemical staining.
- the nipple is first dekeratinized with 5% to 50% acetic acid to remove keratin and other potentially blocking and contaminating substances from the ductal orifices.
- a solution of the labelled antibody preferably an antibody which directly binds to a cytokeratin or other epithelial cytoplasmic or surface membrane marker, such as the antibodies described above, is then applied to the nipple surface.
- the antibody is preferably linked to a fluorescent marker, more preferably fluorescein, and the fluorescein-labelled antibody delivered in a buffered aqueous solution.
- controls may be run.
- labelled antibodies of the same Ig class as the specific antibody may be exposed to the nipple at the same dilution. By comparing the results with the specific antibody and the control antibody, non-specific binding can be discounted.
- the labelling reagent will typically be packaged (optionally with the keratinolytic agent) together with instructions for use in a conventional assay package, such as a box, bottle, tube, pouch, or the like.
- the instructions for use may be written out on a separate instruction sheet or may be partially or fully incorporated onto the packaging materials.
- a second kit according to the present invention will comprise the labelling reagent (optionally with the keratinolytic agent) in a package as set forth above.
- the package will further include an access device capable of being introduced through the ductal orifice, such as a catheter, a fiber optic scope, or the like. Suitable catheters and fiber optic scopes are described in the background art discussed above.
- kits may further comprise instructions for use (IFU) setting forth any of the methods described above.
- Acetic acid is mixed with Velvacrol (50% v/w), a pharmaceutical vehicle comprising an aqueous mixture of petrolatum/mineral oil, acetyl alcohol, sodium laural sulfate, cholesterol, methylparaben, butylparaben, and propylparaben.
- methyl cellulose 100 mg is pre-added to the Velvacrol (5 g).
- the mixture possesses a uniform pasty consistency and is applied to the nipple as an ointment or paste.
- the keratinolytic agent is typically left on the nipple for twenty-four hours or longer to remove the keratin plugs from the ductal orifices.
- the ductal epithelium must be solubilized with 70% by weight ethanol.
- the solubilization step is not necessary.
- a mouse monoclonal primary antibody is used as a dilution of 1:5 to 1:100 and maintained on the nipple for one hour at room temperature. After such incubation, the nipple is washed with phosphate buffered saline PBS and a secondary antibody (fluoresceinated goat anti-mouse antibody) used at a dilution of from 1:5 to 1:1000 fold at room temperature.
- the nipple may be examined under ultraviolet (UV) light at a wavelength selected for the particular fluorochrome being used.
- UV ultraviolet
- a control can then be run using an antibody of a similar class, but without specificity for any of the ductal epithelial or other markers which may be present on the nipple. This method will provide successful labelling of the ductal orifices and permit subsequent cannulation and examination of each orifice.
- Duct cannulation and exploration can be performed under white (visual) light.
- One or more ducts are cannulated first with a rigid metal duct-probe (6 Fr Taber-Rothschild Galactography Kit, Manan Medical Products Inc., Northbrook, Ill.) dilated to 0.45 mm to 0.5 mm.
- a guide wire (0.4 mm) is then inserted, and a catheter passed over the guide wire.
- Physiological saline (0.2 ml to 0.5 ml) is instilled to wash the duct lumen. The washings may be spun down and analyzed cytologically.
- the duct lumen is then dried by injecting 0.2 ml to 0.5 ml air.
- the orifice is held shut by pinching the end of the nipple.
- An endoscope (FVS-3000, M&M Company, Tokyo), which is 0.4 mm in outer diameter is then threaded into the duct orifice while dilation of the duct with air is maintained. After the endoscope is inserted for 5 mm to 10 mm, its position may be confirmed. The cannulization may then be continued as far distally as possible. Desired diagnostic, therapeutic, or other material may then be instilled into the duct.
- the duct may be dilated with saline using a closed system with a burst adapter to allow a better view.
- cells may be removed through the cannula (as washings).
- the collected cells may be processed according to standard cytological methods for similar washings, such as bronchial washings and biopsy specimens.
- the cells may be identified directly or indirectly by histopathological analysis of the duct from which the cells were obtained.
Abstract
Description
- This application is a continuation-in-part application and claims priority under 37 CFR 120 to U.S. application Ser. No. 09/153,564 filed Sep. 15, 1998, which is a continuation-in-part application of U.S. application Ser. No. 08/931,786, filed Sep. 16, 1997, now U.S. Pat. No. 6,168,779; and this application is a continuation-in-part and claims priority under 37 CFR 120 to U.S. application Ser. No. 09/740,561 filed Dec. 19, 2000 which is a continuation application of U.S. application Ser. No. 09/067,661, filed Apr. 28, 1998, now U.S. Pat. No. 6,221,622, the contents of each of which are incorporated herein by reference.
- [0002] The invention disclosed in this application was made with government support under U.S. Army Medical Research Grant Nos. DAMD17-94-J-4281 and DAMD17-96-C-6117. The government may have certain rights in the invention.
- 1. Field of the Invention
- The present invention relates generally to medical methods and devices for accessing body lumens and in particular to methods and apparatus for identifying ductal orifices in human breasts and accessing the ducts through the identified orifices.
- Breast cancer is the most common cancer in women, with well over 100,000 new cases being diagnosed each year. Even greater numbers of women, however, have symptoms associated with breast diseases, both benign and malignant, and must undergo further diagnosis and evaluation in order to determine whether breast cancer exists. To that end, a variety of diagnostic techniques have been developed, the most common of which are surgical techniques including core biopsy and excisional biopsy. Recently, fine needle aspiration (FNA) cytology has been developed which is less invasive than the surgical techniques, but which is not always a substitute for surgical biopsy.
- A variety of other diagnostic techniques have been proposed for research purposes. Of particular interest to the present invention, fluids from the breast ducts have been externally collected, analyzed, and correlated to some extent with the risk of breast cancer. Such fluid collection, however, is generally taken from the surface of the nipple and represents the entire ductal structure. Information on the condition of an individual duct is generally not provided. Information on individual ducts can be obtained through cannulation and endoscopic examination, but such examinations have been primarily in women with nipple discharge or for research purposes and have generally not examined each individual duct in the breast.
- Since breast cancer usually arises from a single ductal system and exists in a precancerous state for a number of years, endoscopy in and fluid collection from individual breast ducts holds great diagnostic promise for the identification of intermediate markers. Much of the promise, however, cannot be realized until access to each and every duct in a patient's breast can be assured. Presently, ductal access may be obtained by a magnification of the nipple and identification of ductal orifice(s) using conventional medical magnifiers, such as magnification loupes. While such magnified examination is relatively simple, it cannot be relied on to identify all orifices. Moreover, the ductal orifices can be confused with other tissue structures, such as sebaceous glands and simple keratin-filled caruncles of the nipple. Thus, before ductal techniques can be further developed for diagnostic, research, or other purposes, it will be useful to provide methods and apparatus which facilitate identification of ductal orifices to distinguish them from other orifices, and allow subsequent ductal access in selected and/or all ducts in each breast.
- 2. Description of the Background Art
- Publications by the inventors herein relating to breast duct access includeLove and Barsky (1996) Lancet 348: 997-999; Love (1992) “Breast duct endoscopy: a pilot study of a potential technique for evaluating intraductal disease,” presented at 15th Annual San Antonio Breast Cancer Symposium, San Antonio, Tex., Abstract 197; Barsky and Love (1996) “Pathological analysis of breast duct endoscoped mastectomies,” Laboratory Investigation, Modern Pathology, Abstract 67. A description of the inventors' breast duct access work was presented in Lewis (1997) Biophotonics International, pages 27-28, May/June 1997.
- Nipple aspiration and/or the introduction of contrast medium into breast ducts prior to imaging are described in Sartorius (1995) Breast Cancer Res. Treat. 35: 255-266; Sartorius et al. (1977) “Contrast ductography for the recognition and localization of benign and malignant breast lesions: An improved technique,” in: Logan (ed.), Breast Carcinoma, New York, Wiley, pp. 281-300; Petrakis (1993) Cancer Epidem. Biomarker Prev. 2: 3-10; Petrakis (1993) Epidem. Rev. 15: 188-195; Petrakis (1986) Breast Cancer Res. Treat. 8: 7-19; Wrensch et al. (1992) Am. J. Epidem. 135: 130-141; Wrensch et al. (1990) Breast Cancer Res. Treat. 15: 39-51; and Wrensch et al. (1989) Cancer Res. 49: 2168-2174. The presence of abnormal biomarkers in fine needle breast aspirates is described in Fabian et al. (1993) Proc. Ann. Meet. Am. Assoc. Cancer Res. 34: A1556. The use of a rigid 1.2 mm ductoscope to identify intraductal papillomas in women with nipple discharge is described in Makita et al. (1991) Breast Cancer Res. Treat. 18: 179-188. The use of a 0.4 mm flexible scope to investigate nipple discharge is described in Okazaki et al. (1991) Jpn. J. Clin. Oncol. 21: 188-193. The detection of CEA in fluids obtained by a nipple blot is described in Imayama et al. (1996) Cancer 78: 1229-1234. Delivery of epithelium-destroying agents to breasts by ductal cannulation is described in WO 97/05898.
- The present invention provides improved methods, kits, and other apparatus for locating breast ducts in the breasts of human female patients. In particular, the methods of the present invention permit reliable identification of the orifices within the nipple of a breast which lead to each of the multiple ductal networks within the breast. By reliably identifying each orifice, all of the ductal networks can be located and subsequently accessed for diagnostic, risk assessment, therapeutic, research, or other purposes.
- In a first aspect of the present invention, a method for locating an orifice of a breast duct comprises labelling ductal cells disposed at the ductal orifice with a visible or otherwise detectable label. The orifice may then be located based on the presence of the label at the orifice. Specific and preferred methods for labeling the orifices are described below in connection with a second aspect of the present invention. After the orifices have been located, an access device, such as a catheter or fiberoptic viewing scope, can be introduced through at least one of the orifices and into the associated breast duct. The method may further comprise introducing the same or a different access device through other orifices, often into each of the orifices to permit diagnosis, treatment, or other evaluation of all of the ductal networks of a breast.
- In a second aspect, the present invention comprises a method for labelling the orifice of a breast duct. The method includes treating a nipple to expose tissue in an orifice of each duct. The treated nipple is then exposed to a labelling reagent capable of specifically binding to a tissue marker characteristic of tissue at the ductal orifice. Binding of the labelling reagent to the tissue results in immobilization of a label at the orifice, permitting subsequent location of the orifice as described above. The treating step preferably comprises washing the nipple with a keratinolytic agent, such as 5% to 50% acetic acid (by weight), to remove keratin-containing materials which normally occlude the duct orifice and which could inhibit binding of the labelling reagent to the tissue marker. The tissue marker is typically characteristic of the ductal epithelium and represents either a membrane antigen or a cytoplasmic antigen. It has been found by the inventors herein that the ductal epithelium extends to within 0.1 mm to 0.2 mm of the nipple orifice and is sufficiently exposed to the surface of the nipple to permit labelling according to the methods of the present invention. Exemplary markers include cytokeratins, such as cytokeratin 8, cytokeratin 18, E cadherin, epithelial membrane antigen (EMA), and the like. Usually, the labelling reagent comprises a polyclonal or monoclonal antibody or other specific binding substance specific for the marker. The antibody may be directly labelled with a visible label, such as a fluorescent label, a dye label, a chemiluminescent label, or the like. Alternatively, the labeling reagent may comprise two or more components, typically including a primary antibody which is specific for the marker and one or more secondary binding substances which bind to the primary antibody and provide a label, optionally a magnified label. For example, the primary antibody may be unlabelled, and a secondary labelled antibody specific for the primary antibody also be provided. As a further alternative, the primary antibody can be labelled with biotin or other hapten, and binding of the label provided via avidin, secondary antibody specific for the hapten, or the like. Numerous specific techniques for labelling of antigenic tissue markers are well known and reported in the immunocytochemical staining literature.
- In a third aspect, a method according to the present invention comprises labelling cellular material at a ductal orifice with a visible label and subsequently accessing the duct through the labelled orifice. The labelling step usually comprises the method set forth above. The accessing step may comprise introducing an access device through at least one of the labelled orifices, and preferably through all of the labelled orifices, where the access device may be a catheter, a fiber optic viewing scope, or the like.
- In a fourth aspect of the present invention, a kit for labelling breast duct orifices comprises a labelling reagent or reagents capable of specifically labelling a cellular marker at the ductal orifice, instructions setting forth a labelling method as described above, and a package containing the labelling reagent and the instructions for use. Usually, the kits of the present invention will further include the keratinolytic agent and any other reagents that may be necessary for performing the method. Instructions for use will set forth the use of all provided reagents and may further set forth the use of agents which are available in the laboratory where the assay is to be performed.
- In a fifth aspect of the present invention, a kit for accessing a breast duct comprises a labelling reagent capable of specifically labelling a ductal orifice and optionally a keratinolytic agent for treating the nipple prior to exposure of the labelling reagent. The kit further comprises an access device capable of being inserted through a labelled ductal orifice to a ductal lumen, such as a catheter, a fiber optic viewing scope, or the like. The kit still further comprises a package containing the labelling reagent, optionally the keratinolytic agent, and the access device. The accessing kit may further comprise instructions for use setting forth a method comprising the accessing steps as described above.
- FIG. 1 is an anterior view of a human female breast, shown in section, and illustrating three of the six to nine ductal networks extending inwardly from the nipple.
- FIG. 2 is an enlarged view of the nipple of FIG. 1 illustrating the orifices leading to each of the three ductal networks.
- FIG. 3 is a still further enlarged view of a single orifice illustrating the distribution of tissue markers from the epithelium to the opening of the orifice, where such markers at the opening are available for binding to labelled antibodies.
- FIG. 4 is a schematic illustration of the appearance of a nipple which has been labelled with visible markers according to the methods of the present invention.
- The present invention comprises methods for locating, labelling, and accessing the ductal networks in human female breasts. A typical breast B is illustrated in FIG. 1 and includes a nipple N and from six to nine ducts D.
- Three ductal networks D1-3 extending inwardly from the nipple N into the breast tissue are illustrated. As best seen in FIG. 2, each ductal network D1-3 begins with an orifice O1-3 which lies at the surface of the nipple N and extends inwardly through a ductal sinus S1-3 and then into a branching network. Each network D comprises a series of successively smaller lumens which are arranged in complex, three-dimensional patterns. The networks of each duct will overlap within the breast tissue but will not be interconnected. The present invention relies on identifying and labelling tissue in the orifice O of each duct D within the nipple N. Usually, there will be from six to nine orifices which open into a like number of ductal networks. An abrupt transition from the ductal epithelium to the squamous epithelium of the skin is found within about 0.1 mm to 0.2 mm of the nipple surface. Typically, the ductal orifice will be occluded with a conical keratin plug measuring about 0.5 mm to 1 mm in size.
- The present invention relies on the specific labelling of tissue markers at the orifice of selected one(s) or all of the ductal network(s). By “specific,” it is meant that the label will be introduced in a manner such that it will bind to the orifice region within the nipple but not bind (or will bind to a significantly lesser extent, usually at least 10-fold less) to other regions of the nipple. In this way, binding of the label to the orifice will be a discernable indication that the orifice is present and available for access to the associated ductal network.
- In a particular aspect of the present invention, the tissue marker(s) will be an antigenic or epitopic site characteristic of the epithelial lining of the breast duct. Surprisingly, it has been found that the epithelial lining extends sufficiently far into the orifice region of the duct to permit successful labelling using generally conventional immunocytochemical labelling reagents and techniques, as described in more detail below. Exemplary tissue markers include antigens and epitopes defined by the cytokeratins present in the epithelial cytoplasmic lining, such as cytokeratin 8, cytokeratin 18, and by molecules present in the membrane lining, such as E cadherin, epithelial membrane antigen (EMA), and the like. Suitable breast epithelial tissue markers are described, for example, in Moll et al. (1982) Cell 30:11-19; Gown and Vogel (1984) Am. J. Pathol. 114:309-321; and Johnson (1991) Cancer Metastasis Rev. 10:11-22.
- Referring now to FIG. 3, an orifice region O of a ductal network D is illustrated with a plurality of markers M lining the epithelium of the duct and extending to the perimeter of the orifice. Labelled antibodies A can be used to locate and label those markers M which are near the orifice O. Frequently, it will be desirable or necessary to wash the nipple with a solution capable of unblocking the orifice to permit binding of the antibodies or other labelling reagent. For example, the orifice can frequently become plugged with keratin-containing materials, and washing with a keratinolytic solution, such as acetic acid (5% to 50% by weight) admixed in a pharmaceutical delivery vehicle, will expose sufficient marker sites at each orifice to enable labelling according to the methods of the present invention.
- The labelled antibodies or other labelling reagents may be formulated as liquid, typically aqueous, solutions in a generally conventional manner. Suitable anti-cytokeratin antibodies may be obtained from commercial suppliers, with specific antibodies including FITC-anticytokeratin (Becton-Dickenson), CAM 5.2, and the like. The antibodies may be coupled to one member of a signal-producing system capable of generating a detectable visual or other change on the tissue surface, where an element will be referred to here and after as a “visual label.” Suitable signal-producing systems include fluorescent systems, color-generating systems, and luminescent systems. Preferred is use of fluorescent systems which comprise a single fluorescent label, but other systems which comprise two or more components including enzymes, substrates, catalysts, enhancers, and the like, may also be employed. At least one component of the signal-producing system will be attached to the antibody or other specific binding substance which is capable of directly or indirectly binding to the tissue marker. Usually, the antibody will bind directly to the tissue marker, but it will also be possible to employ primary antibodies which are specific for the tissue marker and labelled secondary antibodies which introduce the label or component of the signal-producing system. For example, the primary antibody can be mouse IgG and the labelled secondary antibody can be FITC goat anti-mouse IgG (Zymed). Such signal-producing systems and the use on tissue and tissue samples is well described in the medical, scientific, and patent literature relating to immunocytochemical staining.
- In an exemplary protocol according to the present invention, the nipple is first dekeratinized with 5% to 50% acetic acid to remove keratin and other potentially blocking and contaminating substances from the ductal orifices. A solution of the labelled antibody, preferably an antibody which directly binds to a cytokeratin or other epithelial cytoplasmic or surface membrane marker, such as the antibodies described above, is then applied to the nipple surface. The antibody is preferably linked to a fluorescent marker, more preferably fluorescein, and the fluorescein-labelled antibody delivered in a buffered aqueous solution. Optionally, controls may be run. For example, labelled antibodies of the same Ig class as the specific antibody may be exposed to the nipple at the same dilution. By comparing the results with the specific antibody and the control antibody, non-specific binding can be discounted.
- The labelling reagent will typically be packaged (optionally with the keratinolytic agent) together with instructions for use in a conventional assay package, such as a box, bottle, tube, pouch, or the like. The instructions for use may be written out on a separate instruction sheet or may be partially or fully incorporated onto the packaging materials.
- A second kit according to the present invention will comprise the labelling reagent (optionally with the keratinolytic agent) in a package as set forth above. The package will further include an access device capable of being introduced through the ductal orifice, such as a catheter, a fiber optic scope, or the like. Suitable catheters and fiber optic scopes are described in the background art discussed above. Such kits may further comprise instructions for use (IFU) setting forth any of the methods described above.
- The following experimental descriptions are offered by way of illustration, not by way of imitation.
- A. Dekeratinizing the Nipple
- Acetic acid is mixed with Velvacrol (50% v/w), a pharmaceutical vehicle comprising an aqueous mixture of petrolatum/mineral oil, acetyl alcohol, sodium laural sulfate, cholesterol, methylparaben, butylparaben, and propylparaben. To keep the acetic acid in solution, methyl cellulose (100 mg) is pre-added to the Velvacrol (5 g). The mixture possesses a uniform pasty consistency and is applied to the nipple as an ointment or paste. The keratinolytic agent is typically left on the nipple for twenty-four hours or longer to remove the keratin plugs from the ductal orifices.
- B. Labelling of the Ductal Orifice
- For cytoplasmic antigens, the ductal epithelium must be solubilized with 70% by weight ethanol. For a membrane or surface antigen, the solubilization step is not necessary. A mouse monoclonal primary antibody is used as a dilution of 1:5 to 1:100 and maintained on the nipple for one hour at room temperature. After such incubation, the nipple is washed with phosphate buffered saline PBS and a secondary antibody (fluoresceinated goat anti-mouse antibody) used at a dilution of from 1:5 to 1:1000 fold at room temperature. After washing with PBS, the nipple may be examined under ultraviolet (UV) light at a wavelength selected for the particular fluorochrome being used. A control can then be run using an antibody of a similar class, but without specificity for any of the ductal epithelial or other markers which may be present on the nipple. This method will provide successful labelling of the ductal orifices and permit subsequent cannulation and examination of each orifice.
- C. Ductoscopy
- Duct cannulation and exploration can be performed under white (visual) light. One or more ducts are cannulated first with a rigid metal duct-probe (6 Fr Taber-Rothschild Galactography Kit, Manan Medical Products Inc., Northbrook, Ill.) dilated to 0.45 mm to 0.5 mm. A guide wire (0.4 mm) is then inserted, and a catheter passed over the guide wire. Physiological saline (0.2 ml to 0.5 ml) is instilled to wash the duct lumen. The washings may be spun down and analyzed cytologically.
- The duct lumen is then dried by injecting 0.2 ml to 0.5 ml air. At the end of the final insufflation, the orifice is held shut by pinching the end of the nipple. An endoscope (FVS-3000, M&M Company, Tokyo), which is 0.4 mm in outer diameter is then threaded into the duct orifice while dilation of the duct with air is maintained. After the endoscope is inserted for 5 mm to 10 mm, its position may be confirmed. The cannulization may then be continued as far distally as possible. Desired diagnostic, therapeutic, or other material may then be instilled into the duct.
- Alternatively, after cannulation, the duct may be dilated with saline using a closed system with a burst adapter to allow a better view.
- In a particular aspect of the present invention, cells may be removed through the cannula (as washings). The collected cells may be processed according to standard cytological methods for similar washings, such as bronchial washings and biopsy specimens. The cells may be identified directly or indirectly by histopathological analysis of the duct from which the cells were obtained.
- Although the foregoing invention has been described in detail for purposes of clarity of understanding, it will be obvious that certain modifications may be practiced within the scope of the appended claims.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/175,022 US20020164286A1 (en) | 1997-09-16 | 2002-06-19 | Methods for obtaining fluid and cellular material from a breast duct |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/931,786 US6168779B1 (en) | 1997-09-16 | 1997-09-16 | Methods and kits for identifying ductal orifices |
US09/067,661 US6221622B1 (en) | 1998-04-28 | 1998-04-28 | Method and kit for obtaining fluids and cellular material from breast ducts |
US09/153,564 US6455027B1 (en) | 1997-09-16 | 1998-09-15 | Methods and kits for identifying ductal orifices in a nipple |
US09/740,561 US20010001059A1 (en) | 1998-04-28 | 2000-12-19 | Method and kit for obtaining fluids and cellular material from breast ducts |
US10/175,022 US20020164286A1 (en) | 1997-09-16 | 2002-06-19 | Methods for obtaining fluid and cellular material from a breast duct |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/153,564 Continuation-In-Part US6455027B1 (en) | 1997-09-16 | 1998-09-15 | Methods and kits for identifying ductal orifices in a nipple |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020164286A1 true US20020164286A1 (en) | 2002-11-07 |
Family
ID=46278965
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/099,439 Expired - Lifetime US6890311B2 (en) | 1997-09-16 | 2002-03-15 | Methods for performing medical procedures within a breast duct |
US10/175,022 Abandoned US20020164286A1 (en) | 1997-09-16 | 2002-06-19 | Methods for obtaining fluid and cellular material from a breast duct |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/099,439 Expired - Lifetime US6890311B2 (en) | 1997-09-16 | 2002-03-15 | Methods for performing medical procedures within a breast duct |
Country Status (1)
Country | Link |
---|---|
US (2) | US6890311B2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60031114T2 (en) * | 1999-06-11 | 2007-05-03 | Cytyc Corp., Marlborough | LIQUID GEL FORMULATION FOR DETECTING MILK CHANNELS IN THE CHEST BEFORE SURGICAL ABLATION OF THE BREAST TISSUE |
US20050165288A1 (en) * | 2004-01-27 | 2005-07-28 | Scimed Life Systems, Inc. | Systems and methods for treating breast tissue |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US20100204609A1 (en) * | 2009-02-10 | 2010-08-12 | Howard Worth | Microendoscope and methods of use |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5083572A (en) * | 1987-02-04 | 1992-01-28 | Pokorny Susan F | Removal of secretions from the prepubertal vagina |
US5405321A (en) * | 1992-07-07 | 1995-04-11 | William A. Cook Australia Pty. Ltd. | Combined aspiration and flushing coupling |
US5904715A (en) * | 1997-06-13 | 1999-05-18 | John D. Jeter | Breast enhancement apparatus and procedure |
US6413228B1 (en) * | 1998-12-28 | 2002-07-02 | Pro Duct Health, Inc. | Devices, methods and systems for collecting material from a breast duct |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1047107A (en) | 1951-12-26 | 1953-12-11 | Cannula or mask for injections, instillations and similar applications under vacuum | |
US3786801A (en) | 1969-02-24 | 1974-01-22 | Diagnostic Inc | Method and apparatus for aiding in the detection of breast cancer |
US3608540A (en) | 1969-02-24 | 1971-09-28 | St Croix Research Co | Method and apparatus for aiding in the detection of breast cancer |
WO1985003132A1 (en) | 1984-01-06 | 1985-07-18 | The Regents Of The University Of California | Cytokeratin tumor markers and assays for their detection |
SE470273B (en) | 1990-09-24 | 1993-12-20 | Idl Immunodeveloplab Ab | Cytokeratin fragments, their preparation and use, production of monoclonal antibodies and test kits for epithelial cancer |
IT1251542B (en) * | 1991-03-06 | 1995-05-17 | D D S R L | DEVICE FOR THERAPEUTIC OR HYGIENE WASHING OF INTERNAL HUMAN OR ANIMAL BODIES, WHICH ALLOWS THE DRAINAGE OF WASHING LIQUID |
US5413558A (en) | 1991-09-09 | 1995-05-09 | New York University | Selective aortic perfusion system for use during CPR |
US5851830A (en) | 1993-03-16 | 1998-12-22 | University Of Southern California | Luminal epithelial antigen |
US6500114B1 (en) | 1993-11-23 | 2002-12-31 | Dofi Technologies, Inc. | Method of extracting biopsy cells from the breast |
US5650317A (en) | 1994-09-16 | 1997-07-22 | Michigan State University | Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics |
US5763415A (en) | 1995-08-03 | 1998-06-09 | John Hopkins University School Of Medicine | Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer |
WO1997005898A1 (en) | 1995-08-03 | 1997-02-20 | The Johns Hopkins University School Of Medicine | Delivery of an agent to the ductal epithelium in the prophylactic and therapeutic treatment of cancer |
US6221622B1 (en) * | 1998-04-28 | 2001-04-24 | The Regents Of The University Of California | Method and kit for obtaining fluids and cellular material from breast ducts |
US6168779B1 (en) | 1997-09-16 | 2001-01-02 | The Regents Of The University Of California | Methods and kits for identifying ductal orifices |
AU1820100A (en) | 1998-11-13 | 2000-06-05 | Pro Duct Health, Inc. | Devices and methods to identify ductal orifices during nipple aspiration |
-
2002
- 2002-03-15 US US10/099,439 patent/US6890311B2/en not_active Expired - Lifetime
- 2002-06-19 US US10/175,022 patent/US20020164286A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5083572A (en) * | 1987-02-04 | 1992-01-28 | Pokorny Susan F | Removal of secretions from the prepubertal vagina |
US5405321A (en) * | 1992-07-07 | 1995-04-11 | William A. Cook Australia Pty. Ltd. | Combined aspiration and flushing coupling |
US5904715A (en) * | 1997-06-13 | 1999-05-18 | John D. Jeter | Breast enhancement apparatus and procedure |
US6413228B1 (en) * | 1998-12-28 | 2002-07-02 | Pro Duct Health, Inc. | Devices, methods and systems for collecting material from a breast duct |
Also Published As
Publication number | Publication date |
---|---|
US20020160431A1 (en) | 2002-10-31 |
US6890311B2 (en) | 2005-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6168779B1 (en) | Methods and kits for identifying ductal orifices | |
US20010001059A1 (en) | Method and kit for obtaining fluids and cellular material from breast ducts | |
Fritscher-Ravens et al. | Comparison of endoscopic ultrasound-guided fine needle aspiration for focal pancreatic lesions in patients with normal parenchyma and chronic pancreatitis | |
Matsunaga et al. | Mammary ductoscopy for diagnosis and treatment of intraductal lesions of the breast | |
US6750037B2 (en) | Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques | |
CA2395325C (en) | Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques | |
Maier et al. | The clinical value of urinary cytology: 12 years of experience with 615 patients. | |
Stacker et al. | A new breast carcinoma antigen defined by a monoclonal antibody | |
US6890311B2 (en) | Methods for performing medical procedures within a breast duct | |
Tamura et al. | Rapid on-site evaluation by endosonographers during endoscopic ultrasonography-guided fine-needle aspiration for diagnosis of gastrointestinal stromal tumors | |
CN110055300A (en) | A kind of fungal infection detection kit and its application | |
US20020013539A1 (en) | Methods and devices for diagnosis of precancer and cancer in breast milk ducts | |
Luo et al. | Efficacy of indocyanine green fluorescence angiography in preventing anastomotic leakage after McKeown minimally invasive esophagectomy | |
Winkler et al. | Orbital metastasis from prostatic carcinoma: identification by an immunoperoxidase technique | |
Xu et al. | Preclinical evaluation of Mab CC188 for ovarian cancer imaging | |
Farsund et al. | Local chemotherapeutic effects in bladder cancer demonstrated by selective sampling and flow cytometry | |
Despommier | The laboratory diagnosis of Entamoeba histolytica. | |
US20040030264A1 (en) | Method and apparatus for analyzing mammary gland fluid | |
Danforth Jr et al. | Combined breast ductal lavage and ductal endoscopy for the evaluation of the high‐risk breast: A feasibility study | |
Ou et al. | Application of fluorescence endoscopy with methylene blue dye and indocyanine green dual-tracer method in sentinel lymph node biopsy for women with breast cancer | |
Poh et al. | Prostate-specific antigen in breast disease | |
Matsunaga et al. | Intraductal approach to the detection of intraductal lesions of the breast | |
Fu et al. | Improving oral squamous cell carcinoma diagnosis and treatment with fluorescence molecular imaging | |
Chuchueva et al. | THE ASSESSMENT OF A CELLULAR PATTERN OF THE EPITHELIUM AS A DIAGNOSTIC TOOL FOR LARYNGEAL TUMORS DETECTION | |
RU2156461C2 (en) | Method for diagnosing the cases of prostate carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CALIF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOVE, SUSAN M.;BARSKY, SANFORD H.;REEL/FRAME:013026/0598;SIGNING DATES FROM 20020605 TO 20020608 |
|
AS | Assignment |
Owner name: ARMY, UNITED STATES GOVERNMENT, THE , SECRETARY OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE;REEL/FRAME:015237/0436 Effective date: 20040115 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |